M&A Deal Summary

Evotec Acquires Aptuit

On July 30, 2017, Evotec acquired life science company Aptuit from Welsh Carson Anderson & Stowe for 300M USD

Acquisition Highlights
  • This is Evotec’s 11th transaction in the Life Science sector.
  • This is Evotec’s largest (disclosed) transaction.
  • This is Evotec’s 3rd transaction in the United States.
  • This is Evotec’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2017-07-30
Target Aptuit
Sector Life Science
Buyer(s) Evotec
Sellers(s) Welsh Carson Anderson & Stowe
Deal Type Add-on Acquisition
Deal Value 300M USD

Target

Aptuit

Greenwich, Connecticut, United States
website
Aptuit LLC is a provider of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Evotec

Hamburg, Germany

website

Category Company
Founded 1993
Sector Life Science
Employees3,914
Revenue 751M EUR (2022)
DESCRIPTION

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. Evotec was founded in 1993 and is based in Hamburg, Germany.

DEAL STATS #
Overall 12 of 15
Sector (Life Science) 11 of 14
Type (Add-on Acquisition) 9 of 11
State (Connecticut) 1 of 1
Country (United States) 3 of 4
Year (2017) 1 of 1
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-15 Cyprotex

Macclesfield, United Kingdom

Cyprotex PLC is a specialist ADME-Tox Contract Research Organisation, serves the Pharmaceutical and Biotech, Cosmetics/Personal Care and Chemicals Industries as well as academia and not-for-profit organisations.

Buy £55M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-18 Sanofi SA - Infectious diseases

Paris, France

Sanofi SA - Infectious diseases are caused by bacteria, viruses, fungi or parasites and can be spread, directly or indirectly, from one person to another. Treatments for infectious diseases include antibiotics and anti-viral medications. Today, infectious diseases propagated by bacteria are becoming increasingly resistant to many antibiotics and any use of antibiotics reduces the effectiveness of these drugs for other patients. The World Health Organization (“WHO”) has deemed antibiotic resistance to be one of the three greatest threats to human health today. Almost a million people die of resistant infections a year. It is also estimated that by 2050, 10 million lives a year and a cumulative 100 trillion dollars of economic output are at risk due to the rise of drug resistant infections, if solutions to this problem are not identified now. Thus, there is a critical need to research and develop medical solutions to combat antibiotic resistant bacteria.

Buy -

Seller(S) 1

SELLER

Welsh Carson Anderson & Stowe

New York, New York, United States

Investor Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 1979
PE ASSETS 27.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Welsh Carson Anderson & Stowe (WCAS) is a mega-sized, specialist private equity firm focused on investments in growth-oriented companies operating within the healthcare and technology/tech-enabled services industries. WCAS will consider small and large transactions; including venture investments, growth equity investments, buy-and-build transactions, public-to-private acquisitions, and corporate carve-outs. The Firm prefers control situations and generally seeks opportunities in the US. Welsh Carson Anderson & Stowe was formed in 1979 and is based in New York City.

DEAL STATS #
Overall 59 of 73
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 37 of 43
State (Connecticut) 3 of 3
Country (United States) 57 of 70
Year (2017) 1 of 1
Size (of disclosed) 28 of 33
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-02 Intoxalock

Des Moines, Iowa, United States

Intoxalock is a U.S. provider of ignition interlock devices, which are breathalyzers installed in vehicles to prevent ignition by intoxicated drivers. Intoxalock pioneered the development of fuel cell technology in IIDs, and continues to combat drunkdriving with the most innovative solutions in the market.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-19 Kindred

Louisville, Kentucky, United States

Kindred is a healthcare services company based in Louisville, Kentucky. Kindred provides healthcare services in 2,353 locations, including 97 transitional care hospitals, five inpatient rehabilitation hospitals, 98 nursing centers, 21 sub-acute units, 153 Kindred at Home hospice, home health and non-medical home care locations, 104 inpatient rehabilitation units (hospital-based), and a contract rehabilitation services business, RehabCare, which serves 1,875 non-affiliated facilities. Kindred was founded in 1985 and is based in Louisville, Kentucky.

Buy $4.1B
Mergr

Product

Company

Legal